Skip to main content

Novo Nordisk’s Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds

Closely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.